» Articles » PMID: 27568731

Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy

Overview
Journal Curr Pharm Des
Date 2016 Aug 30
PMID 27568731
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

For more than a century, scientists have tried to exploit the anti-tumoral potential of the immune system to treat cancer. However, clinical success was traditionally limited. Consequently, classical anti-neoplastic treatments such as surgery, radiotherapy, and chemotherapy used to be the first line of treatment. Fortunately, this scenario is changing, particularly with the identification of immune checkpoint inhibitors. Now more than ever, it becomes essential to understand how cancer cells modulate the immune system. In this review, we summarize main mechanisms of antigen presentation in the tumor microenvironment, a main event in the establishment of anti-tumor immunity. Specifically, we focus on recent progress in mechanisms involved in tumor antigen presentation, as well as on strategies cancer cells develop to favor immune suppressive and immune tolerant enironments. In addition, we briefly discuss current therapeutic approaches to overcome tumor immune evasion.

Citing Articles

Pulsed electric field ablation as a candidate to enhance the anti-tumor immune response to immune checkpoint inhibitors.

Arciga B, Walters D, Kimchi E, Staveley-OCarroll K, Li G, Teixeiro E Cancer Lett. 2024; 609:217361.

PMID: 39608443 PMC: 11625606. DOI: 10.1016/j.canlet.2024.217361.


Designing, cloning and simulation studies of cancer/testis antigens based multi-epitope vaccine candidates against cutaneous melanoma: An immunoinformatics approach.

Khalid S, Guo J, Muhammad S, Bai B Biochem Biophys Rep. 2024; 37:101651.

PMID: 38371523 PMC: 10873875. DOI: 10.1016/j.bbrep.2024.101651.


An immunometabolism subtyping system identifies S100A9 macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis.

Bao X, Wang D, Dai X, Liu C, Zhang H, Jin Y Cell Rep Med. 2023; 4(4):100987.

PMID: 36990096 PMC: 10140461. DOI: 10.1016/j.xcrm.2023.100987.


Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies.

Rahni A, Jaago M, Sadam H, Pupina N, Pihlak A, Tuvikene J Commun Med (Lond). 2022; 2:48.

PMID: 35603273 PMC: 9095616. DOI: 10.1038/s43856-022-00114-7.


Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.

Zhang Z, Zhang X, Huang A Front Oncol. 2021; 11:718589.

PMID: 34485153 PMC: 8416150. DOI: 10.3389/fonc.2021.718589.